In early March, the Cambridge, Mass.-based drugmaker said a 48-week study involving 664 ALS patients found the drug was safe and well-tolerated, but the clinical trial did not confirm overall efficacy. The FDA approved the therapy in September 2022, and Amylyx is working with officials in the U.S. and Canada to voluntarily discontinue the drug.
After discussing the results with advocacy organizations, patients, caregivers and global experts, Amylyx said patients who wish to stay on the treatment can do so for free after consulting with their physicians.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
